|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 950 F Street, NW |
Address2 | Suite 300 |
City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 31350-12
|
||||||||
|
6. House ID# 306540000
|
TYPE OF REPORT | 8. Year | 2009 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Paul J. Larsen, Deputy Compliance Officer & Assistant General Counsel |
Date | 07/20/2009 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.R. 2346, Supplemental Appropriations Act, 2009: pandemic flu funding
H.R. 2847, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2010: trade infringement
H.R. 2892, Department of Homeland Security Appropriations Act, 2010: importation
H.R. 2997, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2010: importation, FDA funding
S. 1298, Department of Homeland Security Appropriations Act, 2010: importation
H.Con.Res. 85, 2010 Budget Resolution: health care reform funding provisions
S.Con.Res.13, 2010 Budget Resolution: health care reform funding provisions
Labor - Health and Human Services - Education Appropriations for Fiscal Year 2010: comparative effectiveness, NIH funding, pandemic flu funding
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maya |
Bermingham |
|
|
|
Robert |
Filippone |
|
|
|
Bryant |
Hall |
|
|
|
Mimi |
Kneuer |
|
|
|
Thomas |
Moore |
|
|
|
Brian |
Nagle |
|
|
|
Byron |
Patterson |
|
|
|
Lori |
Reilly |
|
|
|
Richard |
Smith |
|
|
|
Matt |
Sulkala |
|
|
|
Billy |
Tauzin |
|
|
|
Steve |
Tilton |
|
|
|
Valerie |
Jewett |
|
Leg. Director - Rep. Rodney Frelinghuysen |
|
Jennifer |
Swenson |
|
Staff Assist., Leg. Correspondent, Leg. Assist., |
|
" |
" |
|
Deputy Leg. Director - Senator Pat Roberts |
|
David |
Boyer |
|
Special Assist. to the President for Legislative |
|
" |
" |
|
Affairs - White House, Assist. Comm'r for |
|
" |
" |
|
Legislation - FDA, Special Assist. for Over- |
|
" |
" |
|
sight - HHS, Special Assist. to the Secretary - |
|
" |
" |
|
HHS, Special Assist. in Office of Assist. |
|
" |
" |
|
Secretary for Legislation - HHS, Special Assist. |
|
" |
" |
|
in Office of White House Liaison - Dept. of |
|
" |
" |
|
Defense, Confidential Assist. in Office of |
|
" |
" |
|
Secretary - Dept. of Labor |
|
Lea |
Fisher |
|
Leg. Assist. - Rep. Bob Etheridge |
|
Gregory |
Gierer |
|
Leg. Assist., Leg. Correspondent - Sen. |
|
" |
" |
|
Christopher Dodd, Staff Assist. - Rep. Rosa |
|
" |
" |
|
DeLauro |
|
Kendra |
Martello |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
H.R. 1260, Patent Reform Act of 2009: patent reform issues including obtaining a patent, post-grant review, and patent litigation
H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics
H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics
H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009: patent settlements
S. 299, To establish a pilot program in certain United States district courts to encourage enhancement of expertise in patent cases among district judges: establishing a pilot program for district court judges concerning patent litigation
S. 369, Preserve Access to Affordable Generics Act: patent settlements
S. 515, Patent Reform Act of 2009: patent reform issues including obtaining a patent, post-grant review, and patent litigation
S. 610, Patent Reform Act of 2009: patent reform issues including obtaining a patent, post-grant review, and patent litigation
S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics
International intellectual property issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Patent & Trademark Office (PTO), U.S. Trade Representative (USTR), Commerce - Dept of (DOC), Federal Trade Commission (FTC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Robert |
Filippone |
|
|
|
Bryant |
Hall |
|
|
|
Mimi |
Kneuer |
|
|
|
David |
Korn |
|
|
|
Hallie |
Maranchick |
|
|
|
Thomas |
Moore |
|
|
|
Brian |
Nagle |
|
|
|
Byron |
Patterson |
|
|
|
Lori |
Reilly |
|
|
|
Richard |
Smith |
|
|
|
Heather |
Strawn |
|
|
|
Matt |
Sulkala |
|
|
|
Billy |
Tauzin |
|
|
|
Steve |
Tilton |
|
|
|
Jennifer |
Van Meter |
|
|
|
Michael |
Woody |
|
Professional Staff - Senate HELP Committee |
|
David |
Boyer |
|
Special Assist. to the President for Legislative |
|
" |
" |
|
Affairs - White House, Assist. Comm'r for |
|
" |
" |
|
Legislation - FDA, Special Assist. for Over- |
|
" |
" |
|
sight - HHS, Special Assist. to the Secretary |
|
" |
" |
|
HHS, Special Assist. in Office of Assist. |
|
" |
" |
|
Secretary for Legislation - HHS, Special Assist. |
|
" |
" |
|
in Office of White House Liaison - Dept. of |
|
" |
" |
|
Defense, Confidential Assist. in Office of |
|
" |
" |
|
Secretary - Dept. of Labor |
|
Lea |
Fisher |
|
Leg. Assist. - Rep. Bob Etheridge |
|
Anne |
Pritchett |
|
Senior Policy Analyst - White House Drug |
|
" |
" |
|
Policy Office, Executive Office of the Pres. |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 1, American Recovery and Reinvestment Act of 2009: comparative effectiveness
H.R. 444, 340B Program Improvement and Integrity Act: issues related to 340B program (drug pricing program for covered entities)
H.R. 759, Food and Drug Administration Globalization Act of 2009: import safety
H.R. 1256, Family Smoking Prevention and Tobacco Control Act: importation
H.R. 1298, Pharmaceutical Market Access and Drug Safety Act of 2009: importation
H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics
H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics
H.R. 1859, Independent Drug Education and Outreach Act of 2009: academic detailing
H.R. 2502, Comparative Effectiveness Research Act of 2009: comparative effectiveness
H.R. 2824, Doctor-Patient Relationship and Research Protection Act: comparative effectiveness
House Tri-Committee Health Reform Discussion Draft
S. 1, American Recovery and Reinvestment Act of 2009: comparative effectiveness
S. 350, American Recovery and Reinvestment Act of 2009: comparative effectiveness
S. 422, The Heart Disease Education, Analysis Research, and Treatment (HEART) for Women Act: new drug application requirements
S. 488, Access to Cancer Clinical Trials Act of 2009, access to clinical trials
S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009: importation
S. 717, 21st Century Cancer ALERT (Access to Life-Saving Early detection, Research and Treatment) Act: reimbursement and clinical trial issues
S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics
S. 767, Independent Drug Education and Outreach Act of 2009: academic detailing
S. 882, Drug and Device Accountability Act of 2009: import safety
S. 914, Cures Acceleration Network and National Institutes of Health Reauthorization of 2009: basic research and development
S. 1142, Informed Health Care Decision Making Act: drug labeling
S. 1213, Patient-Centered Outcomes Research Act of 2009: comparative effectiveness
S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009: importation
S. __, Affordable Health Choices Act: health reform, regulatory approval pathway for follow on biologics, 340B program issues
Confirmation of Kathleen Sebelius for Department of Health and Human Services Secretary
Confirmation of Margaret Hamburg for Commissioner of Food and Drugs
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, White House Office, Natl Economic Council (NEC), Health & Human Services - Dept of (HHS), Federal Trade Commission (FTC), Congressional Budget Office (CBO), Agency for Health Care Policy & Research, Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maya |
Bermingham |
|
|
|
Randy |
Burkholder |
|
|
|
Andrea |
Douglas |
|
|
|
Robert |
Filippone |
|
|
|
Bryant |
Hall |
|
|
|
Ann |
Kaplan |
|
|
|
Mimi |
Kneuer |
|
|
|
Hallie |
Maranchick |
|
|
|
Thomas |
Moore |
|
|
|
Brian |
Nagle |
|
|
|
Byron |
Patterson |
|
|
|
Lori |
Reilly |
|
|
|
Richard |
Smith |
|
|
|
Heather |
Strawn |
|
|
|
Matt |
Sulkala |
|
|
|
Billy |
Tauzin |
|
|
|
Steve |
Tilton |
|
|
|
Jennifer |
Van Meter |
|
|
|
Michael |
Woody |
|
Professional Staff - Senate HELP Committee |
|
Valerie |
Jewett |
|
Leg. Director - Rep. Rodney Frelinghuysen |
|
David |
Boyer |
|
Special Assist. to the President for Legislative |
|
" |
" |
|
Affairs - White House, Assist. Comm'r for |
|
" |
" |
|
Legislation - FDA, Special Assist. for Over- |
|
" |
" |
|
sight - HHS, Special Assist. to the Secretary - |
|
" |
" |
|
HHS, Special Assist. in Office of Assist. |
|
" |
" |
|
Secretary for Legislation - HHS, Special Assist. |
|
" |
" |
|
in Office of White House Liaison - Dept. of |
|
" |
" |
|
Defense, Confidential Assist. in Office of |
|
" |
" |
|
Secretary - Dept. of Labor |
|
Jennifer |
Swenson |
|
Staff Assist., Leg. Correspondent, Leg. Assist., |
|
" |
" |
|
Deputy Leg. Director - Senator Pat Roberts |
|
Lea |
Fisher |
|
Leg. Assist. - Rep. Bob Etheridge |
|
Anne |
Pritchett |
|
Senior Policy Analyst - White House Drug |
|
" |
" |
|
Policy Office, Executive Office of the Pres. |
|
Gregory |
Gierer |
|
Leg. Assist., Leg. Corresp. - Sen. Christopher |
|
" |
" |
|
Dodd, Staff Assist. - Rep. Rosa DeLauro |
|
Daniel |
Durham |
|
Acting Dep. Assist. Sec. Health Policy, Dep. to |
|
" |
" |
|
Dep. Assist. Sec. Health Policy, Senior Advisor |
|
" |
" |
|
Health Policy - HHS, Acting Assoc. Comm'r & |
|
" |
" |
|
Dep. Assoc. Comm'r Retirement Policy - SSA, |
|
" |
" |
|
Policy Analyst & Budget Examiner - OMB |
|
Kendra |
Martello |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 2, Childrens Health Insurance Program Reauthorization Act of 2009: SCHIP reauthorization, Medicaid rebate, 340B
H.R. 684, Medicare Prescription Drug Savings and Choice Act: Part D issues
H.R. 904, Medicaid Prescription Drug Rebate Equalization Act of 2009: managed care organization (MCO) rebate
H.R. 1788, False Claims Act Correction Act of 2009: liability issues
S. 275, Childrens Health Insurance Reauthorization Act of 2009: SCHIP reauthorization,
Medicaid rebate
S. 301, Physician Payments Sunshine Act of 2009: transparency issues
S. 330, Medicare Prescription Drug Savings and Choice Act: Part D issues
S. 458, False Claims Act Clarification Act of 2009: liability issues
S. 1110, Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009: Medicare payment issues
Health care reform issues
Senate Finance Committee options papers
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Agency for Health Care Policy & Research, Health & Human Services - Dept of (HHS), Congressional Budget Office (CBO), Medicare Payment Advisory Commission (MedPAC), White House Office, Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maya |
Bermingham |
|
|
|
Randy |
Burkholder |
|
|
|
Andrea |
Douglas |
|
|
|
Bryant |
Hall |
|
|
|
Valerie |
Jewett |
|
Leg. Director - Rep. Rodney Frelinghuysen |
|
Ann |
Kaplan |
|
|
|
Mimi |
Kneuer |
|
|
|
Hallie |
Maranchick |
|
|
|
Thomas |
Moore |
|
|
|
Brian |
Nagle |
|
|
|
Byron |
Patterson |
|
|
|
Lori |
Reilly |
|
|
|
Richard |
Smith |
|
|
|
Heather |
Strawn |
|
|
|
Matt |
Sulkala |
|
|
|
Billy |
Tauzin |
|
|
|
Steve |
Tilton |
|
|
|
Jennifer |
Van Meter |
|
|
|
Michael |
Woody |
|
Professional Staff - Senate HELP Committee |
|
Jennifer |
Swenson |
|
Staff Assist., Leg. Correspondent, Leg. Assist., |
|
" |
" |
|
Dep. Leg. Director - Sen. Pat Roberts |
|
David |
Boyer |
|
Spec. Assist. to Pres. for Leg. Affairs - White |
|
" |
" |
|
House, Assist. Comm'r for Leg. - FDA, Special |
|
" |
" |
|
Assist. for Oversight - HHS, Spec. Assist. to |
|
" |
" |
|
Sec. - HHS, Spec. Assist. in Office of Assist. |
|
" |
" |
|
Sec. for Legis. - HHS, Spec. Assist. in Office |
|
" |
" |
|
of White House Liaison - Dept. of Defense, |
|
" |
" |
|
Conf. Assist. in Office of Sec. - Dept. of Labor |
|
Lea |
Fisher |
|
Leg. Assist. - Rep. Bob Etheridge |
|
Gregory |
Gierer |
|
Leg. Assist., Leg. Corresp. - Sen. Christopherr |
|
" |
" |
|
Dodd, Staff Assist. - Rep. Rosa DeLauro |
|
Daniel |
Durham |
|
Acting Dep. Assist. Sec. Health Policy, Deputy |
|
" |
" |
|
to Deputy Assist. Sec. Health Policy, Senior |
|
" |
" |
|
Advisor Health Policy - HHS, Acting Assoc. |
|
" |
" |
|
Comm'r & Dep. Assoc. Comm'r Retirement |
|
" |
" |
|
Policy - SSA, Policy Analyst & Budget |
|
" |
" |
|
Examiner - OMB |
|
Jennifer |
Bryant |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
H.R. 3012, Trade Reform, Accountability, Development, and Employment Act of 2009 (TRADE Act of 2009): trade agreements
Korea Free Trade Agreement: intellectual property, market access and public health
Peru Free Trade Agreement: intellectual property, market access and public health
U.S. Assistance for Global HIV/AIDS Programs
International market access and intellectual property issues
Trade enforcement issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, U.S. Trade Representative (USTR), Commerce - Dept of (DOC), State - Dept of (DOS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Robert |
Filippone |
|
|
|
Thomas |
Moore |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENV
16. Specific lobbying issues
H.R. 1145, National Water Research and Development Initiative Act of 2009: water issues
H.R. 1191, Safe Drug Disposal Act of 2009: drug take back
H.R. 1359, Secure and Responsible Drug Disposal Act of 2009: drug take back
S. 1005, Water Infrastructure Financing Act: water issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE,
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kendra |
Martello |
|
|
|
Brian |
Nagle |
|
|
|
Valerie |
Jewett |
|
Leg. Director - Rep. Rodney Frelinghuysen |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
5 |
|
||||||
2 |
|
6 |
|
||||||
3 |
|
7 |
|
||||||
4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address: http://www.phrma.org/about_phrma/member_company_list/members/
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 3 | 5 |
2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 5 | 9 |
2 | 6 | 10 |
3 | 7 | 11 |
4 | 8 | 12 |